Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MOTIF BIO PLC. We currently have 60 research reports from 6 professional analysts.
|08Feb17 07:00||RNS||Director/PDMR Shareholding|
|07Feb17 07:02||RNS||Director/PDMR Shareholding|
|31Jan17 07:00||RNS||Clinical trial finishes patient treatment phase|
|27Jan17 18:13||RNS||Holding(s) in Company|
|18Jan17 07:05||RNS||Director/PDMR Shareholding|
|18Jan17 07:00||RNS||Appointment of Chief Financial Officer|
|09Jan17 17:28||RNS||Issue of Equity|
Frequency of research reports
Research reports on
MOTIF BIO PLC
MOTIF BIO PLC
01 Feb 17
"The FOMC’s Monetary Policy Statement, which is due at 19:00hrs GMT, will likely be today’s principal talking point. Not that any change in the discount rate is anticipated, but traders will be listening acutely for any suggestion as to when the first of 2017’s three anticipated hikes might kick-off. This will be particularly sensitive for the US$, which yesterday slid to its lowest level against the international basket since Trump’s election was seen to drive the currency to a 14-year high in November. While there may be some truth in the idea that month-end rebalancing by forex traders somewhat weighed on the Dollar, suggestions from President Trump that Japan and China are devaluing their currencies to boost international trade, while a US trade advisor tells the FT that Germany benefits from a ‘grossly undervalued’ Euro, hints that there are some early signs of panic in the White House. Yet the reality of Trump’s rallying call ‘America First’ is founded on inward looking, reflationary and protectionist policies, which are destined primarily to power the US$ ever upward, and something that even Donald might find he can do very little to stop. The damage inflicted on the Mexican Peso after its government drew swords with the President was a clear warning to all US trading partners, but most particularly China, of troubles ahead. Reflecting on this, the Dow Jones remained yesterday’s main casualty, with the other principal US indices closing with just fractional movements. Catching up following the Lunar New Year break, the Hang Seng fell quite sharply, reflecting also news that China’s Manufacturing PMI fell for the second straight month in January. Elsewhere in Asia, the Nikkei recovered from an early setback to close slightly in the positive, while the ASX gained as commodity plays and financials marginally firmed. Other than the Nationwide Housing Prices index, there is little UK macro data due today, although January Markit Manufacturing PMI figures cover most EU territories, including Great Britain. At 10:00hrs GMT, the European commission is also due to release its Economic Growth Forecasts, while later a large batch of US statistics, including ISM Manufacturing, Construction Spending and Vehicle Sales for January, precede this evening’s Fed decision. UK corporates due to release earnings or trading updates include AG Barr (BAG.L), Low & Bonar (LWB.L) and TalkTalk (TALK.L). With the US$ now trading off yesterday’s lows, London equities are expected to recoup some of yesterday’s losses, with the FTSE-100 seen rising some 30 points during opening business. Investors will also be keeping a weary eye out for reports from the Commons this morning, with as many as 100 MPs reportedly planning to vote against a law to trigger Article 50. " - Barry Gibb, Research Analyst
Patient treatment completed in REVIVE-1
31 Jan 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), a late clinical stage antibiotic development company, has announced that the treatment phase has finished for the last patient in REVIVE-1, the first of two phase III clinical trials of iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI). With this news Motif Bio is firmly on-track to report headline results from the trial in Q2. We believe iclaprim remains a highly valuable new antibiotic and take the rapid enrolment of patients in this trial as an indicator of the strong clinical need for a product with its performance characteristics, particularly for patients with renal impairment (some 26% of the estimated 3.6m hospitalized ABSSSI patients in the USA annually). Our fair value estimate for Motif Bio stands at 107p.
Further de-risking of iclaprim
31 Jan 17
Motif is a clinical stage development company focused on a best-in-class drug that targets bacteria resistant to most other commonly used antibiotics. The FDA has agreed a plan of two carefully constructed Phase III trials that will allow approval of iclaprim, opening it up to a $3.0bn market segment. The company has just achieved an important milestone with the last patient completing treatment in the REVIVE-1 trial, which keeps in on its revised (earlier) schedule to release headline data in 2Q 2017. Following a recent NASDAQ IPO and EU Placing, the company has sufficient capital to complete the first trial (REVIVE-1).
Update post NASDAQ IPO
20 Jan 17
Motif Bio (LSE: MTFB, NASDAQ: MTFB), is a late clinical stage antibiotic development company. The company completed its IPO on NASDAQ in November last year raising $25m before expenses. With the funds from the IPO the company is now funded to completion of REVIVE-1, the first of its two phase III clinical trials of its lead drug candidate, iclaprim. This antibiotic is being developed for the treatment of serious and life threatening bacterial infections, particularly those caused by drug resistant bacteria. It is a next-generation antibiotic targeting an under-utilised mechanism of action which causes rapid killing of bacteria making it an attractive candidate for acute infections. Given our belief in iclaprim showing positive results in REVIVE-1 and Motif’s current share price, we think an investment now would be timely with REVIVE-1 on-track to report soon (Q2’17). Our risk-adjusted fair value estimate for Motif Bio now stands at £210m (107p per share).
Consistently strong growth at a sensible price
24 Feb 17
In “Alice in Wonderland”, Lewis Carroll tells the story of a girl, who falls through a rabbit hole into a world populated by peculiar, anthropomorphic creatures. Here, Alice crosses swords with the Queen of Hearts, meets the Cheshire Cat and is invited to the "Mad Hatters” tea party, which she subsequently discovers is “stupid”.
£21m equity raise to accelerate growth
22 Feb 17
Blindly following what others do is often a recipe for disaster. However, when an army of ‘super smart’ fund managers snap-up a big holding in a rapidly expanding small-cap that owns ‘disruptive’ technology addressing multi-$billion markets, then it is usually worth taking note. This is exactly what has happened at Kromek, a next generation radiation detection firm. Having just successfully completed its oversubscribed £20m placing and £1m open offer at 20p/share - supported by esteemed investors such as Gervais Williams at Miton (largest shareholder at 19.0%) and Katie Potts (Herald 5.35%), as well as several others such as Schroders (5.0%) and Killik (4.1%).
Interim results – adhering to international growth strategy
23 Feb 17
Interim results showed a strong performance for Tristel, 6% ahead of its AGM statement on 12 December at which it indicated adjusted pre-tax profits to be no less than £1.6m. Revenues increased by 22% (16% at constant exchange rates – CER or 12% CER excluding the impact of the Australian acquisition) and adjusted pre-tax profits were up 15% to £1.71m. Despite the strong half, we leave our full-year forecasts unchanged, given FX uncertainty and a one-off stocking order in H1 from the NHS, although at current FX rates the risk to our forecasts is considered to be to the upside. However, we raise our target price by 10% to 165p to reflect the solid progress as well as rolling forward our multiples to calendar-adjusted 2017.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
N+1 Singer - Anpario - Feed for growth
24 Feb 17
Anpario’s natural animal feed additive product offering is well placed to benefit from the increasing demand for animal protein and tightening regulations around antibiotic use as growth promoters. The group is in a transition phase, building strong commercial relationships with end users, which we believe should benefit the margin. Anpario’s geographical diversity is a key positive and with a strong balance sheet there is potential for acquisitive as well as organic growth. We initiate coverage with a 354p Target Price and a Buy recommendation ahead of FY results on 8th March.
N+1 Singer - Morning Song 23-02-2017
23 Feb 17
Genus (GNS LN) Interim results: R&D step-up, disappointing ABS performance | Howden Joinery Group (HWDN LN) Prelims and net cash better than expected but conditions weaken | Oxford Pharmascience Group (OXP LN) Encouraging interim OXPzero™ Ibuprofen exploratory PK data | StatPro Group (SOG LN) Increased majority shareholding in Infovest Consulting | Wilmington Group (WIL LN) Interims slightly ahead, move to focus on 3 verticals